Abstract
Clinical cases have been reported of tacrolimus (FK506)-induced QT prolongation. We have previously demonstrated sustained QT prolongation by FK506 in guinea pigs. Herein, we aimed to conduct a pharmacokinetic/pharmacodynamic (PK/PD) analysis of FK506, using a model involving the myocardial compartment. The pharmacokinetics of FK506 and its effects on QTc intervals were investigated in guinea pigs. In the pharmacokinetic study, whole blood and ventricular FK506 concentrations were analyzed, using a 4-compartment model during and after intravenous infusion of FK506 (0.01 or 0.1 mg/hr/kg). Subsequently, the concentration–response relationship between ventricular FK506 concentration and change in QTc interval was analyzed, using the maximal effect (Emax) model. Pharmacokinetic profiles of FK506 showed a delayed distribution of FK506 into the ventricle. Furthermore, the observed QT prolongation paralleled the ventricular FK506 concentrations, with no lag-time between the two. The Emax model successfully described the relationship between changes in QTc interval and ventricular FK506 concentrations. In conclusion, the PK/PD model where the myocardial drug concentration of FK506 was linked with its adverse effect could describe, for the first time, the anti-clockwise hysteresis observed in the relationship between blood FK506 concentration and QT prolongation. Such a hysteresis pattern for QT prolongation might be caused, therefore, mainly by the delayed disposition of FK506 to ventricular myocytes.
Similar content being viewed by others
REFERENCES
T. S. Faber, M. Zehender, and H. Just. Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf. 11:463–476 (1994).
W. Crumb and I. Cavero. QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. Pharm. Sci. Technol. Today 2:270–280 (1999).
M. C. Johnson, S. So, J. W. Marsh, and A. M. Murphy. QT prolongation and torsades de pointes after administration of FK506. Transplantation 53:929–930 (1992).
S. P. Hodak, J. B. Moubarak, I. Rodriguez, M. C. Gelfand, M. R. Alijani, and C. M. Tracy. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplantation 66:535–537 (1998).
T. Minematsu, H. Ohtani, H. Sato, and T. Iga. Sustained QT prolongation induced by tacrolimus in guinea pigs. Life Sci. 65:PL197–PL202 (1999).
H. Derendorf and B. Meibohm. Modeling of pharmacokinetic_pharmacodynamic (PK_ PD) relationships: concepts and perspectives. Pharm. Res. 16:176–185 (1999).
H. Ohtani, E. Hanada, K. Yamamoto, Y. Sawada, and T. Iga. Pharmacokinetic–pharmacodynamic analysis of the electrocardiographic effects of terfenadine and quinidine in rats. Biol. Pharm. Bull. 19:1189–1196 (1996).
H. Ohtani, H. Kotaki, Y. Sawada, and T. Iga. A comparative pharmacokinetic–pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. J. Pharm. Pharmacol. 49:458–462 (1997).
M. Hirota, H. Ohtani, E. Hanada, H. Kotaki, Y. Sawada, and T. Iga. Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. Life Sci. 62:2159–2169 (1998).
E. Hanada, H. Ohtani, H. Kotaki, Y. Sawada, H. Sato, and T. Iga. Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. J. Pharm. Sci. 88:234–240 (1999).
H. Ohtani, H. Sato, T. Iga, H. Kotaki, and Y. Sawada. Pharmacokinetic–pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. Biopharm. Drug. Dispos. 20:101–106 (1999).
T. Minematsu, H. Ohtani, H. Sato, and T. Iga. Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. Biol. Pharm. Bull. 22:1341–1346 (1999).
H. C. Bazzet. An analysis of the time-relations of electrocardiograms. Heart 7:353–370 (1920).
E. Hayes, M. K. Pugsley, W. P. Penz, G. Adaikan, and M. J. Walker. Relationship between QaT and RR intervals in rats, guinea pigs, rabbits, and primates. J. Pharmacol. Toxicol. Methods 32:201–207 (1994).
W. J. Jusko, A. W. Thomson, J. Fung, P. McMaster, S. H. Wong, E. Zylber-Katz, U. Christians, M. Winkler, W. E. Fitzsimmons, R. Lieberman, J. McBride, M. Kobayashi, V. Warty, and S. J. Soldin. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther. Drug Monit. 17:606–614 (1995).
Y. Sawada, M. Hanano, Y. Sugiyama, H. Harashima, and T. Iga. Prediction of the volumes of distribution of basic drugs in humans based on data from animals. J. Pharmacokinet. Biopharm. 12:587–596. (1984).
S. H. Snyder, M. M. Lai, and P. E. Burnett. Immunophilins in the nervous system. Neuron 21:283–294 (1998).
W. H. duBell, P. A. Wright, W. J. Lederer, and T. B. Rogers. Effect of the immunosupressant FK506 on excitation–contraction coupling and outward K +currents in rat ventricular myocytes. J. Physiol. 501:509–516 (1997).
W. H. duBell, S. T. Gaa, W. J. Lederer, and T. B. Rogers. Independent inhibition of calcineurin and K +currents by the immunosuppressant FK-506 in rat ventricle. Am. J. Physiol. 275:H2041–H2052 (1998).
A. A. Grace and A. J. Camm. Quinidine. N. Engl. J. Med. 338:35–45 (1998).
H. Zhang, B. Zhu, J. A. Yao, and G. N. Tseng. Differential effects of S6 mutations on binding of quinidine and 4-aminopyridine to rat isoform of Kv1.4: common site but different factors in determining blockers' binding affinity. J. Pharmacol. Exp. Ther. 287:332–343 (1998).
D. Rampe and M. K. Murawsky. Blockade of the human cardiac K +channel Kv1.5 by the antibiotic erythromycin. Naunyn-Schmiedebergs Arch. Pharmacol. 355:743–750 (1997).
S. Zhang, Z. Zhou, Q. Gong, J. C. Makielski, and C. T. January. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res. 84:989–998 (1999).
M. Taglialatela, A. Pannaccione, P. Castaldo, G. Giorgio, Z. Zhou, C. T. January, A. Genovese, G. Marone, and L. Annunziato. Molecular basis for the lack of HERG K + channel block-related cardiotoxicity by the H 1receptor blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol. 54:113–121 (1998).
W. H. duBell, W. J. Lederer, and T. B. Rogers. K +currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin. Am. J. Physiol. 278:H886–H897 (2000).
J. P. Steiner, T. M. Dawson, M. Fotuhi, C. E. Glatt, A. M. Snowman, N. Cohen, and S. H. Snyder. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 358:584–587 (1992).
N. H. Holford, P. E. Coates, T. W. Guentert, S. Riegelman, and L. B. Sheiner. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration–effect relationships. Br. J. Clin. Pharmacol. 11:187–195 (1981).
J. A. Bennett, Y. C. Clancy, and J. D. McNeish. Identification and characterization of the murine FK506 binding protein (FKBP) 12.6 gene. Mamm. Genome. 9:1069–1071 (1998).
G. S. Hamilton and J. P. Steiner. Immunophilins: beyond immunosuppression. J. Med. Chem. 41:5119–5143 (1998).
K. Yokogawa, M. Takahashi, I. Tamai, H. Konishi, M. Nomura, S. Moritani, K. Miyamoto, and A. Tsuji. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm. Res. 16:1213–1218 (1999).
A. T. Fojo, K. Ueda, D. J. Slamon, D. G. Poplack, M. M. Gottesman, and I. Pastan. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84:265–269 (1987).
A. Nishiura, T. Murakami, Y. Higashi, and N. Yata. Role of acidic phospholipids in tissue distribution of quinidine in rats. J. Pharmacobiodyn. 10:134–141 (1987).
D. J. Morgan, and J. L. Huang. Albumin decreases myocardial permeability of unbound quinidine in perfused rat heart. J. Pharmacol. Exp. Ther. 268:283–290 (1994).
S. Shibasaki, K. Komoriya, S. Gon, Y. Matsuura, R. Nishigaki, and K. Umemura. Effects of cimetidine on quinidine distribution in rats. J. Pharmacobiodyn. 10:719–726 (1987).
L. L. Peeters, G. Grutters, and C. B. Martin. Distribution of cardiac output in the unstressed pregnant guinea pig. Am. J. Obstet. Gynecol. 138:1177–1184 (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minematsu, T., Ohtani, H., Yamada, Y. et al. Quantitative Relationship Between Myocardial Concentration of Tacrolimus and QT Prolongation in Guinea Pigs: Pharmacokinetic/Pharmacodynamic Model Incorporating a Site of Adverse Effect. J Pharmacokinet Pharmacodyn 28, 533–554 (2001). https://doi.org/10.1023/A:1014460404352
Issue Date:
DOI: https://doi.org/10.1023/A:1014460404352